These novel medications , Semaglutide , represent a remarkable advancement in managing type 2 diabetes and possibly other conditions . They all are classified as GLP-1 pathway stimulators, indicating these substances to emulate the body's GLP-1 peptide, stimulating insulin secretion and reducing